Article

Patient-tailored design of AML cell subpopulation-selective drug combinations

2020-07-29

Abstract excerpt

The extensive primary and secondary drug resistance in acute myeloid leukemia (AML) requires rational approaches to design personalized combinatorial treatments that exploit patient-specific therapeutic vulnerabilities to optimally target disease-driving AML cell subpopulations. However, the large number of AML-relevant drug combinations makes the testing impossible in scarce primary patient cells. This combinator...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 535c0dd4-e59e-54af-8631-ed786dd94b83
DOI: 10.1101/2020.07.28.222034

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Patient-tailored design of AML cell subpopulation-selective drug combinationsDOI 10.1101/2020.07.28.222034Read

Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.Semantic proximity Read

Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clonesSemantic proximity Read

A Methodological Workflow to Analyze Synthetic Lethality and Drug Synergism in Cancer Cells.Semantic proximity Read

Beyondcell: targeting cancer therapeutic heterogeneity in single-cell RNA-seqSemantic proximity Read

Synergistic and antagonistic drug interactions are prevalent but not conserved across acute myeloid leukemia cell linesSemantic proximity Read

Methods for High-Throughput Drug Combination Screening and Synergy ScoringSemantic proximity Read

Synergistic and antagonistic drug interactions are prevalent but not conserved across acute myeloid leukemia cell linesSemantic proximity Read

Identifying effective drug combinations for patients with acute myeloid leukemia.Semantic proximity Read

[Performing integrative transcriptomic and chemical screening to identify patient-specific vulnerabilities in poor-prognosis acute myeloid leukemia].Semantic proximity Read

Integration of Pan-Cancer Cell Line and Single-Cell Transcriptomic Profiles Enables Inference of Therapeutic Vulnerabilities in Heterogeneous TumorsSemantic proximity Read

Anticancer Target Combinations: Network-Informed Signaling-Based Approach to DiscoverySemantic proximity Read

A cancer pharmacogenomic screen powering crowd-sourced advancement of drug combination predictionSemantic proximity Read